Skip to Main Content

In a fit of anger, drug makers are urging the Food and Drug Administration to delay a final rule giving the agency greater leeway to police off-label marketing over concerns it would harm public health by “chilling valuable scientific speech,” according to a recently filed petition.

The rule, which was issued last month, says drug makers must update product labeling if there is evidence indicating a company intended its medicine to be used off-label, or for an unapproved use. Doctors are free to prescribe drugs for any purpose, while court rulings determined drug companies can make statements about off-label uses only if the information provided is truthful and not misleading.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED